1 Min Read
Dec 21 (Reuters) - Beigene Ltd :
* Says announced dosing of first patient in a phase I clinical trial of BGB-290 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.